Skip to content

Clinical trials

Lymphoma, Large B-Cell, Diffuse trials in China with unknown status

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Lymphoma, Large B-Cell, Diffuse Status: Unknown status Country / region: China Clear all

116 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20081
20102
20121
20134
20155
201618
201712
20187
20199
202012
202111
202216
202317
20241

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status116

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Ruijin Hospital17
Fudan University7
The First Affiliated Hospital with Nanjing Medical University6
Chinese PLA General Hospital4
Nanfang Hospital, Southern Medical University4
PersonGen BioTherapeutics (Suzhou) Co., Ltd.4
Sun Yat-sen University4
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.3
Mingzhi Zhang3
Second Affiliated Hospital, Zhejiang University, School of Medicine3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Lymphoma, Large B-Cell, Diffuse116
Lymphoma, Follicular15
Lymphoma, Mantle-Cell15
Leukemia, Lymphocytic, Chronic, B-Cell11
Recurrence7
Lymphoma, B-Cell6
Lymphoma, Non-Hodgkin5
Hematologic Neoplasms4
Leukemia, Prolymphocytic3
Leukemia, Prolymphocytic, B-Cell3

Trials

Showing 1 to 25 of 116. Each trial links to its page on Pharma Observatory.

16 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.